linjc16/ctgov huggingface dataset:
Association Between Child's Psychological Resilience and Practicing Oral Habits

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to determine the effect of psychological resilience on practicing oral habits among a group of 5- to 7-year-old children.

Detailed Description
-----------------
Psychological pressure has been thought to be a predisposing factor that might result in deleterious oral habits practicing. Shahraki et al. stated that increased stress levels are associated with oral habits as thumb sucking and nail biting. Leme et al. concluded that children and adolescents with DOH presented more symptoms of depression than their counterparts. Moreover, they were more likely to report symptoms of anxiety. Ability to cope (or resilience) includes a person's sense of agency and their ability to think and behave, to make positive decisions, and to apply skills and knowledge to life challenges. The term resilience has come to mean an individual's ability to overcome adversity and continue his or her normal development. The association between psychological resilience and practicing oral habits in children remains unclear, this study aims to reveal that association, if present.

Official Title
-----------------
Association Between Child's Psychological Resilience and Practicing Oral Habits: Cross Sectional Study

Conditions
-----------------
Oral Habits

Intervention / Treatment
-----------------
* Other: Child and Youth Resilience Measure - Revised (CYRM-R)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medically free children Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>Medically free children aged from 5 years to 7 years and do not practice oral habits. | Other: Child and Youth Resilience Measure - Revised (CYRM-R)<br>* (CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent<br>* Other names: Person Most Knowledgeable (PMK);|
| Oral habit practicing group<br>Medically free children aged from 5 years to 7 years and practicing oral habits. | Other: Child and Youth Resilience Measure - Revised (CYRM-R)<br>* (CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent<br>* Other names: Person Most Knowledgeable (PMK);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psychological resilience | Measured by: Child & Youth Resilience Measure - Revised It Consists of 17 questions answered by the child, choices optiones scored as (No = 1 , sometimes = 2, Yes = 3) The upper limit of the score is 51 and the lower limit is 17 the higher the score the higher the psychological resilience that the child has. | Base line, subject will asked to fill the questionnaire for once |
Comparison of Conventional With Sonography Assisted Breast Surgery After Neoadjuvant Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Aim of the study is to investigate whether intra-surgical visualisation of malignoma reduces the resection rate in the case of R1 resection compared to the procedure without sonographic visualisation

Official Title
-----------------
Sonographically Assisted Versus Conventionally Breast Surgery in Breast Cancer Patients With an Indication for Breast Conserving Surgery After Neoadjuvant Chemotherapy

Conditions
-----------------
Breast Cancer Surgery

Intervention / Treatment
-----------------
* Procedure: Sonographically assisted breast surgery
* Procedure: Conventional breast surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 80 years Female Presurgical validated breast cancer Unifocal to multifocal findings Palpable and/o non-palpable findings Neoadjuvant chemotherapy Indication for breast conserving therapy General operation ability and anesthesia ability Consent to conventional breast conserving breast surgery with wire marking Ability and will to follow the study conditions Written declaration of consent after clarification Exclusion Criteria: Sonographically not clearly delineate resection areal Exclusion criteria for breast conserving therapy Simultaneous participation in other interventional trials that interfere with this study at the investigator's discretion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sonographically assisted breast surgery<br>Sonography assisted breast surgery | Procedure: Sonographically assisted breast surgery<br>* Sonography<br>Procedure: Conventional breast surgery<br>* Conventional<br>|
| Active Comparator: Conventional breast surgery<br>Conventional breast surgery | Procedure: Sonographically assisted breast surgery<br>* Sonography<br>Procedure: Conventional breast surgery<br>* Conventional<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| R0 resection rate | proportion of surgical procedures for cancer in which the surgeon is able to completely remove all detectable tumor tissue with negative margins, indicating that no cancer cells remain in the surgical site | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight of primary resedate | weight of the tumor tissue removed during surgery for cancer | 3 years | 
| Time for cut and sew | duration of the surgical procedure from the initial incision to the completion of the closure of the incision site | 3 years |
Evaluation of of a Prefixed 50% N2O- 50%O2 Mixture in Legal Abortion Under Local Analgesia

Study Overview
=================
Brief Summary
-----------------
To evaluate effectiveness of a prefixed 50% N2O- 50%O2 mixture in legal abortion under paracervical block.

Official Title
-----------------
Evaluation of of a Prefixed 50% N2O- 50%O2 Mixture in Legal Abortion Under Local Analgesia

Conditions
-----------------
Abortion

Intervention / Treatment
-----------------
* Drug: 50% N2O- 50%O2 mixture
* Drug: Placebo (air)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major patient having signed an assent waits having chosen to make the intervention under local anesthetic Exclusion Criteria: Minor contraindication in the use of the paracetamol, the lidocaine Porphyries

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>50% N2O- 50%O2 mixture administration during the intervention | Drug: 50% N2O- 50%O2 mixture<br>* 50% N2O- 50%O2 mixture administration<br>|
| Placebo Comparator: 2<br>Placebo (air) during the intervention | Drug: Placebo (air)<br>* Placebo administration during the intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain during the intervention |  | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain at the end of the intervention and 2 hours after. Unwanted events |  | 4 months |
Development of the Partial Pressure of Carbon Dioxide During Exercise and at Night in Patients With Chronic Obstructive Pulmonary Disease (COPD) IV

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the development of partial pressure of carbon dioxide during the 6-min walking test and during night in Chronic Obstructive Pulmonary Disease (COPD)-patients (GOLD stage IV). Therefore the partial pressure of carbon dioxide, oxygen saturation and the heart rate are registered by a device called Sentec during the mentioned periods. In addition a measurement of activity is realised by an activity monitor (Sensewear).

Official Title
-----------------
Development of the Partial Pressure of Carbon Dioxide During 6-min Walking Test and at Night in Patients With Chronic Obstructive Pulmonary Disease IV

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Procedure: 6-minute walking test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD IV with and without a respiratory insufficiency maximal paCO² of 55mmHg at admission (taken at rest by blood gas analysis without LTOT) Exclusion Criteria: paCO² > 55mmHg non-invasive ventilation acute exacerbation

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: exercise testing<br>6-minute walking test with pCO2 and pO2 measurement | Procedure: 6-minute walking test<br>* submaximum exercise test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase of PaCO2 more than 5mmHg |  | From time of starting 6-minute walking test until the time of PaCO2-increase of more than 5mmHg assessed up to 6 minutes. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of PaCO2 |  | From the beginning of the 6-minute walking test until peak PaCO2, assessed up to 6 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, carbon dioxide, 6-minute walking test
Photodynamic Therapy in Treatment of Verrucae

Study Overview
=================
Brief Summary
-----------------
To assess the efficacy (clinically and dermoscopically) and safety of photodynamic therapy using intralesional injection of 4% methylene blue solution as a photosensitizer with IPL versus IPL only in treatment of warts.

Detailed Description
-----------------
This study will be conducted on: Eighty patients suffering of verruca (male and female) divided randomly into three groups: group A, B&C : Group A: 30 patients will undergo photodynamic therapy using intralesional 4%methylene blue solution and IPL. Group B: 30 patients will undergo IPL only. Group C (control group):20 patients will undergo intralesional saline.

Official Title
-----------------
PHOTODYNAMIC THERAPY USING METHYLENE BLUE AND INTENSE PULSED LIGHT VERSUS INTENSE PULSED LIGHT ALONE IN TREATMENT OF VERRUCA :A RANDOMIZED CONTROLLED STUDY

Conditions
-----------------
Verruca Vulgaris

Intervention / Treatment
-----------------
* Other: methylene blue / IPL
* Other: IPL
* Other: saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age:Above 16 years old. Sex:Both males and female patients. Clinically and dermoscopically documented verruca. No verruca treatment in the last 2 weeks. Exclusion Criteria: History of photosensitivity disorder. Pregnant and lactating females. Diseases with risk of koebnerization e.g. Psoriasis and Lichen planus. Anogenital warts. Warts on head and neck.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: methylene blue/IPL<br>will undergo photodynamic therapy using intralesional 4%methylene blue solution ,after a period of 15 minutes the patient will be subjected to IPL session. This will be repeated biweekly until complete clearance of the lesion or a maximum four sessions. | Other: methylene blue / IPL<br>* therapeutic<br>|
| Experimental: IPL<br>will undergo biweekly IPL sessions only until complete clearance of the lesion or a maximum four sessions. | Other: IPL<br>* therapeutic<br>|
| Placebo Comparator: saline<br>will undergo intralesional saline. | Other: saline<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disappearance of verruca | clinical and dermoscopic cure | 10 weeks |
Persistence of Antibody Response to N. Meningitidis Group C in Children

Study Overview
=================
Brief Summary
-----------------
Persistence of Antibody Response to N. meningitidis Group C in Children

Official Title
-----------------
A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule

Conditions
-----------------
Prevention of Meningococcal Infection

Intervention / Treatment
-----------------
* Biological: Meningococcal C conjugate vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy children Exclusion Criteria: previous ascertained or suspected disease caused by N. meningitidis previous significant acute or chronic infections any other serious disease

Ages Eligible for Study
-----------------
Minimum Age: 7 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Meningococcal C conjugate vaccine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immunogenicity: serum antibody responses, as measured by bactericidal activity,using hBCA |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate and compare persistence of antibody response to N. meningitidis serogroup C as measured by serum bactericidal activity |  |  | 
| safety and tolerability |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention of Meningococcal Meningitis, vaccines, conjugate, immunology, child, antibody persistence
Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS)

Study Overview
=================
Brief Summary
-----------------
Mortality in Acute Respiratory Distress Syndrome is high (40 to 60 %). Protective mechanical ventilation, until 2010, was the cornerstone of the ARDS therapeutic strategies. Recently, a prospective multicenter study demonstrates that a 48h continuous infusion of neuromuscular blocking agents (NMBA) have a positive impact on mortality of ARDS patients. (Papazian et al. ACURASYS Study. NEJM 2010; 363:1107-16). The mechanisms through which NMBAs could improve survival remain speculative. They are as follows: reduction of the consumption of oxygen linked to ventilatory workload; increase of chest wall compliance improving mechanical ventilation during ARDS and better adaptation to the protective ventilation strategy; anti-inﬂammatory effect contributing to a reduction in pulmonary inﬂammation and improvement in oxygenation, reduction of the variations of transpulmonary pressure (TPP) by the way of better synchronisation between patient and the ventilator. The use of NMBA could also reduce the ventilator induced lung injury by a better control of TPP.

Official Title
-----------------
Effects of NMBA on the Alteration of Transpulmonary Pressures at the Early Phase of ARDS

Conditions
-----------------
Acute Respiratory Distress Syndrome

Intervention / Treatment
-----------------
* Drug: NIMBEX
* Drug: NIMBEX
* Other: WITHOUT NIMBEX


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Early (< 48H) Severe ARDS: PaO2 / FiO2 ratio < 150 with PEEP >= 5 cmH20 Exclusion Criteria: Age < 18 ans Patient already under continuous infusion NMBA. Known NMBA Allergy or intolerance Contra-indication to introduction of nasogastric tube

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: severe ARDS patients<br> | Drug: NIMBEX<br> <br> |
| Active Comparator: control group<br> | Drug: NIMBEX<br> <br> Other: WITHOUT NIMBEX<br> <br> |
| Experimental: moderate SDRA patients<br> | Drug: NIMBEX<br> <br> Other: WITHOUT NIMBEX<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delta TPP | Reduction of Delta TPP at 48 hr in the NMBA group by comparison with the control group in ARDS patients | 27 months |
Does Topical Lidocaine Decrease Sweat During Exercise in the Heat?

Study Overview
=================
Brief Summary
-----------------
Subjects will walk on a treadmill at 3 mph and sweat will be collected from both forearms. One arm will be pretreated with topical lidocaine, and the other will act as the control.

Detailed Description
-----------------
Subjects will walk on a treadmill at 3 mph and sweat will be collected from both forearms. One arm will be pretreated with topical lidocaine, and the other will act as the control. Sweat will be collected via macroducts attached to each arm. Sweat production on each arm will be compared using t-tests.

Official Title
-----------------
Does Topical Lidocaine Decrease Sweat During Exercise in the Heat?

Conditions
-----------------
Sweat Pore Closure

Intervention / Treatment
-----------------
* Drug: Lidocaine
* Other: control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-35 years of age - Exclusion Criteria: pregnant females -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lidocaine pretreated skin<br>one arm will be pretreated with lidocaine before exercise in the heat | Drug: Lidocaine<br>* effect of lidocaine on sweat production during exercise in the heat<br>Other: control<br>* one arm will be pretreated with topical lidocaine, the other arm will not<br>|
| No Intervention: control skin<br>the other arm will act as the control condition | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| volume of sweat produced during exercise following topical lidocaine | Volume of sweat produced during exercise following tipocal lidocaine | one hour of exercise | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thermoregulation, sweating, exercise
Swiss Study on Spider Bites

Study Overview
=================
Brief Summary
-----------------
About spider bites in Middle Europe, there are published only a dozen cases. The investigators suspect that they may be much more frequent than reflected by the literature analysis (but much less dangerous than thought by people). From June 1st 2011 to November 30st 2012 the investigators collect clinical data on patients treated for spider bites in Switzerland.

Detailed Description
-----------------
Inclusion criteria: Every human treated for suspected spider bite in Switzerland willing to participate this study.

Official Title
-----------------
Swiss Study on Spider Bites

Conditions
-----------------
Spider Bite

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult or child treated for a suspected spider bite in Switzerland Exclusion Criteria: unwillingness to participate to the study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Spider bite patients<br>All patients treated for an actual spider bite by a Swiss physician during study period. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical follow up of bite lesions. | Clinical evolutions of actual spider bite lesions in humans are observed. | 14 days (or more if necessary) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time spread of spider bites | Frequencies of spider bites over the study period of 18 months are observed. | 18 months | 
| Causative animals | To determine spider species causing bites in Switzerland by sending spider specimens to an expert arachnologist. | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
humans, insect bites